Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

0
161
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination.
Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy
adults, and rapid specific T-cell responses were noted from day 14 post-vaccination.

Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here